



Docket No.: A080 US

RECEIVED

NOV 20 2002

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the Application of:

Examiner:

TBD

Browning, et al.

Group Art Unit:

1633

Serial No.: 10/077,137

Filing Date: February 15, 2002

For: BAFF RECEPTOR (BCMA), AN IMMUNOREGULATORY AGENT

CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on:

11/14/2002

Date

Jacqueline L. Marlier

SUPPLEMENTAL COMMUNICATION

RECEIVED

NOV 20 2002

TECH CENTER 1600/2900

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:


The attached Information Statement Disclosure submitted herewith is being filed before the mailing date of a first Office Action on the merits and therefore no fee is due. In an abundance of caution, however, the Assistant Commissioner is hereby authorized to charge Deposit Account No. 02-2327 for any unforeseen fee that may be due.

In addition to the attached Information Statement Disclosure submitted herewith, Applicants are including a copy of the International Search Report issued for PCT application number PCT/US00/22507, on which the instant U.S. application is based.

If the Examiner believes that consideration of the application, or of any matter related to this submission, would be facilitated by a telephone conference with Applicants' attorney, the Examiner is urged to contact the undersigned at the telephone number set forth below.

Respectfully submitted,

Date: 11/14/02



Timothy P. Linkkila

Reg. No. 40,702

BIOGEN, INC.

14 Cambridge Center


Cambridge, MA 02142

(617) 679-3795 (Direct)

(617) 679-2838 (Facsimile)

Please type a plus sign (+) inside this box → ☐

PTO/SB/08B (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet **2** of **2**

Complete if Known

Application Number	10/077,137
Filing Date	2/15/2002
First Named Inventor	Browning, Jeffrey
Group Art Unit	1633
Examiner Name	TBD
Attorney Docket Number	A080 US

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CA	Gras et al., "BCMAp: an Integral Membrane Protein in the Golgi Apparatus of Human Mature B Lymphocytes", International Immunology, Vol. 7, No. 7, 1995, pgs. 1093-1106.	
	CB	Gross et al., "TACI and BCMA are Receptors for a TNF Homologue Implicated in B-Cell Autoimmune Disease", Nature, Vol. 404, April 27 2000, pgs. 995-999.	
	CC	Kwon et al., "Functions of Newly Identified Members of the Tumor Necrosis Factor Receptor/Ligand Superfamilies in Lymphocytes", Current Opinion in Immunology, 1999, pgs. 340-345.	
	CD	Laabi et al., "A New Gene, BCM, on Chromosome 16 is Fused to the Interleukin 2 Gene by a (4;16) (q26;p13) Translocation in a Malignant T Cell Lymphoma", The EMBO Journal, Vol. 11, No. 11, 1992, pgs. 3897-3904.	
	CE	Laabi et al., "The BCMA Gene, Preferentially expressed during B Lymphoid Maturation, is Bidirectionally Transcribed", Nucleic Acids Research, Vol. 22, No. 7, 1994, pgs. 1147-1154.	
	CF	Maldry et al., "The Characterization of Murine BCMA Gene Defines it as a New Member of the Tumor Necrosis Factor Receptor Superfamily", International Immunology, Vol. 10, No. 11, 1998, pgs. 1693-1702.	
	CG	Pitti et al., "Genomic Amplification of a Decoy Receptor for Fas Ligand in Lung and Colon Cancer", Nature, Vol. 396, December 17 1998, pgs. 699-703.	
	CH	Schneider et al., "BAFF, a Novel Ligand of the Tumor Necrosis Factor Family, Stimulates B Cell Growth", J. Exp. Med., Vol. 189, No. 11, June 7 1999, pgs. 1747-1756.	
	CI	Thompson et al., "BAFF Interacts with the Orphan Receptor, BCMA", Scandinavian Journal of Immunology, Vol. 51 (supplement 1), 2000, pg. 65.	
	CJ	Thompson et al., "BAFF Binds to the Tumor Necrosis Factor Receptor-like Molecule B Cell Maturation Antigen and is Important for Maintaining the Peripheral B Cell Population", J. Exp. Med., Vol. 192, No. 1, July 3, 2000, pgs. 129-135.	

RECEIVED

NOV 20 2002

TECH CENTER 1600/2900

Examiner Signature

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.